ArticleTherapeutic advances in gastroenterology2012
Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders.
Article in Therapeutic advances in gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 172 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
172 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Probiotics and gastrointestinal disorders: an umbrella meta-analysis of therapeutic efficacy.European journal of medical research · 2025Pooled it
- Probiotic sepsis in preterm neonates-a systematic review.European journal of pediatrics · 2022Pooled it
- Impact of Saccharomyces boulardii on acute gastrointestinal toxicities in patients undergoing pelvic radiotherapy for gynecologic cancers: a randomized controlled trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Trial
- The effect of probiotic supplementation on the clinical and para-clinical findings of multiple sclerosis: a randomized clinical trial.Scientific reports · 2023Trial
- Efficacy of aloe vera and probiotic mouthwashes vs fluoride mouthwash on Streptococcus mutans in plaque around brackets of orthodontic patients: a randomized clinical trial.The Angle orthodontist · 2023Trial
- Effectiveness of Saccharomyces boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic Sclerosis.Digestive diseases and sciences · 2020Trial
- Trial
- Rethinking probiotics: breaking theGut microbes · 2026Review
- Genome-informed qPCR tracking revealed preferential persistence ofMicrobiology spectrum · 2026Article
- Prophylactic administration of probiotic strains Weizmannia coagulans and Saccharomyces boulardii attenuates early dysplastic changes in an AOM/DSS-induced mouse model.BMC microbiology · 2026Article
- Non-Conventional Yeasts with Probiotic Potential: Diversity, Functional Role, Sustainable Bioprocessing and Local Relevance.Microorganisms · 2026Review
- Article
- Genomic and Phenotypic Evaluation of Safety, Probiotic Potential, and Aroma Production ofMolecules (Basel, Switzerland) · 2026Article
- Targeted and quantitatively modeled biologic delivery via dual-functional probiotic yeast in inflammatory bowel disease.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- Evaluation of Health-Related Quality of Life in Patients Treated with Synbiotics: a Prospective Observational Study.Maedica · 2026Article
- Article
- A Review of Probiotic Interventions for Necrotizing Enterocolitis and Sepsis in Preterm Infants.International journal of molecular sciences · 2026Review
- Comprehensive in vitro probiotic screening and ITS-based molecular identification and characterization of yeast strains isolated from agro-industrial and rumen sources.BMC microbiology · 2026Article
- Molecular Genetics and Probiotic Mechanisms of Saccharomyces cerevisiae var. boulardii.Probiotics and antimicrobial proteins · 2026Review
- Sex differences in immune modulation: implications for infection, inflammation, and nutritional supplementation.Biology of sex differences · 2026Review
112 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Several clinical trials and experimental studies strongly suggest a place for Saccharomyces boulardii as a biotherapeutic agent for the prevention and treatment of several gastrointestinal diseases. S. boulardii mediates responses resembling the protective effects of the normal healthy gut flora. The multiple mechanisms of action of S. boulardii and its properties may explain its efficacy and beneficial effects in acute and chronic gastrointestinal diseases that have been confirmed by clinical trials. Caution should be taken in patients with risk factors for adverse events. This review discusses the evidence for efficacy and safety of S. boulardii as a probiotic for the prevention and therapy of gastrointestinal disorders in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.